Atlanta-based CorMatrix has received CE Mark approval to market in European Union its CorMatrix ECM for Cardiac Tissue Repair, an cellular bioscaffold made of porcine small intestinal submucosa which is surgically implanted at the site of cardiac tissue injury to provide structural support and allow cardiac tissue to gradually remodel and repair itself.
From the company:
CorMatrix’s ECM for Cardiac Tissue Repair is used to repair heart structures during open heart surgery — such as closing a hole in the heart (known as atrial septal defect or ASD). During surgery, CorMatrix ECM is sutured onto the heart tissue in need of repair. It then serves as a scaffold, enabling the body’s own cells to infiltrate and ultimately replace and remodel the implanted ECM with native tissue. The anatomy is restored naturally through the course of the body’s innate wound healing process. It works differently than other available surgical materials, as CorMatrix ECM allows for repair of damaged tissue without leaving permanent synthetic or foreign materials in the body, which can result in unwanted effects.
CorMatrix ECM for Cardiac Tissue Repair is routinely used for:
- Suture line reinforcing
- Buttressing for soft tissue reapproximation
- Aortic cannulation sites
- Cardioplegia cannulation site
- Right atrium cannulation site
- Aortotomy reinforcement
- Ventricular reinforcement
- Cardiac Tissue Repair Septal defect repair
CorMatrix ECM Technology has been commercially available in the U.S. since 2006 and has been implanted in nearly 20,000 cardiac surgery procedures at more than 300 hospitals in the U.S.
From the archives: Novel Surgical Biomaterial Receives Regulatory Approvals